Literature DB >> 21898178

Evaluation of a new automated chemiluminescence immunoassay for FGF23.

Yuichiro Shimizu1, Seiji Fukumoto, Toshiro Fujita.   

Abstract

Fibroblast growth factor 23 (FGF23) is a hormone regulating phosphate and vitamin D metabolism. We have previously established a sandwich enzyme-linked immunosorbent assay (ELISA) for FGF23 and reported that FGF23 values are useful for the differential diagnosis of chronic hypophosphatemia. However, this ELISA has a rather narrow assay range of 3-800 pg/ml, and it was pointed out that the assay performance is not satisfactory when automatic washing is used. Here we evaluated a new automated chemiluminescence immunoassay for FGF23. This assay uses 10 μl sera or plasma samples and requires 20 min to obtain the first result. The assay was linear up to about 15,000 pg/ml and had a detection limit of 1 pg/ml. In addition, this assay showed coefficients of variation of less than 5% using samples with average FGF23 levels of 43.2-2,454.0 pg/ml. When FGF23 levels in 210 samples from chronic hypophosphatemic patients were evaluated by both the previous ELISA and this new assay, there was a good correlation of R (2) = 0.96. However, FGF23 levels by the new assay showed lower values, especially in samples with high FGF23 levels. Given that the lowest FGF23 level in patients with FGF23-related hypophosphatemia was 30.8 pg/ml and that the highest FGF23 levels in patients with non-FGF23-related hypophosphatemia was 20.8 pg/ml by this novel assay, the sensitivity and specificity were 100% when the cutoff was set between 20.8 and 30.8 pg/ml. From the aspect of convenience and the coefficients of variation of this assay, we propose that the cutoff be 25 pg/ml. There results indicate that this new assay is ideal for both clinical use and clinical studies, especially when measuring many samples with high FGF23 levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21898178     DOI: 10.1007/s00774-011-0306-4

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  20 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.

Authors:  N Ito; Y Shimizu; H Suzuki; T Saito; T Okamoto; M Hori; M Akahane; S Fukumoto; T Fujita
Journal:  J Intern Med       Date:  2010-10       Impact factor: 8.989

3.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

4.  Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.

Authors:  Yaacov Frishberg; Nobuaki Ito; Choni Rinat; Yuji Yamazaki; Sofia Feinstein; Itaru Urakawa; Paulina Navon-Elkan; Rachel Becker-Cohen; Takeyoshi Yamashita; Kaori Araya; Takashi Igarashi; Toshiro Fujita; Seiji Fukumoto
Journal:  J Bone Miner Res       Date:  2007-02       Impact factor: 6.741

5.  Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

Authors:  Junichiro J Kazama; Fuminori Sato; Kentaro Omori; Hitomi Hama; Suguru Yamamoto; Hiroki Maruyama; Ichiei Narita; Fumitake Gejyo; Takeyoshi Yamashita; Seiji Fukumoto; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

6.  A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.

Authors:  Kaori Araya; Seiji Fukumoto; Rebecca Backenroth; Yasuhiro Takeuchi; Kounosuke Nakayama; Nobuaki Ito; Nozomi Yoshii; Yuji Yamazaki; Takeyoshi Yamashita; Justin Silver; Takashi Igarashi; Toshiro Fujita
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

7.  Relationship between circulating FGF23 and total body atherosclerosis in the community.

Authors:  Majd A I Mirza; Tomas Hansen; Lars Johansson; Håkan Ahlström; Anders Larsson; Lars Lind; Tobias E Larsson
Journal:  Nephrol Dial Transplant       Date:  2009-05-09       Impact factor: 5.992

8.  Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.

Authors:  Itsuro Endo; Seiji Fukumoto; Keiichi Ozono; Noriyuki Namba; Hiroyuki Tanaka; Daisuke Inoue; Masanori Minagawa; Toshitsugu Sugimoto; Mika Yamauchi; Toshimi Michigami; Toshio Matsumoto
Journal:  Bone       Date:  2008-03-05       Impact factor: 4.398

Review 9.  Bone as an endocrine organ.

Authors:  Seiji Fukumoto; T John Martin
Journal:  Trends Endocrinol Metab       Date:  2009-06-21       Impact factor: 12.015

10.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

View more
  13 in total

Review 1.  The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations.

Authors:  Annemieke C Heijboer; Etienne Cavalier
Journal:  Calcif Tissue Int       Date:  2022-06-04       Impact factor: 4.333

2.  Fibroblast Growth Factor 23 and Mortality Among Prevalent Hemodialysis Patients in the Japan Dialysis Outcomes and Practice Patterns Study.

Authors:  Hirotaka Komaba; Douglas S Fuller; Masatomo Taniguchi; Suguru Yamamoto; Takanobu Nomura; Junhui Zhao; Brian A Bieber; Bruce M Robinson; Ronald L Pisoni; Masafumi Fukagawa
Journal:  Kidney Int Rep       Date:  2020-08-20

Review 3.  The use of fibroblast growth factor 23 testing in patients with kidney disease.

Authors:  Edward R Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

4.  Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure.

Authors:  Miki Imazu; Hiroyuki Takahama; Makoto Amaki; Yasuo Sugano; Takahiro Ohara; Takuya Hasegawa; Hideaki Kanzaki; Toshihisa Anzai; Naoki Mochizuki; Hiroshi Asanuma; Masanori Asakura; Masafumi Kitakaze
Journal:  Hypertens Res       Date:  2016-09-29       Impact factor: 3.872

5.  Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23.

Authors:  Nobuaki Ito; Takuo Kubota; Sachiko Kitanaka; Ikuma Fujiwara; Masanori Adachi; Yasuhiro Takeuchi; Hitomi Yamagami; Takehide Kimura; Tatsuya Shinoda; Masanori Minagawa; Ryo Okazaki; Keiichi Ozono; Yoshiki Seino; Seiji Fukumoto
Journal:  J Bone Miner Metab       Date:  2021-07-13       Impact factor: 2.626

Review 6.  Regulation of male fertility by the bone-derived hormone osteocalcin.

Authors:  Gerard Karsenty; Franck Oury
Journal:  Mol Cell Endocrinol       Date:  2013-10-19       Impact factor: 4.102

7.  Association of BAP with urinary albumin excretion in postmenopausal, but not premenopausal, non-CKD Japanese women.

Authors:  Etsuko Ozaki; Shinsuke Yamada; Nagato Kuriyama; Daisuke Matsui; Isao Watanabe; Teruhide Koyama; Yasuo Imanishi; Masaaki Inaba; Yoshiyuki Watanabe
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

8.  Significance of urinary C-megalin excretion in vitamin D metabolism in pre-dialysis CKD patients.

Authors:  Norikazu Toi; Masaaki Inaba; Eiji Ishimura; Naoko Tsugawa; Yasuo Imanishi; Masanori Emoto; Yoshiaki Hirayama; Shinya Nakatani; Akihiko Saito; Shinsuke Yamada
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379

Review 9.  FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.

Authors:  Anna Kurpas; Karolina Supeł; Karolina Idzikowska; Marzenna Zielińska
Journal:  Dis Markers       Date:  2021-05-17       Impact factor: 3.434

10.  Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia.

Authors:  Shunsuke Goto; Hideki Fujii; Keiji Kono; Kentaro Watanabe; Kentaro Nakai; Shinichi Nishi
Journal:  Clin Kidney J       Date:  2016-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.